Adverse Effects
-
{
- All
- News
- Videos
- Web Stories
-
Kim Kardashian Says She Takes 35 Supplements A Day; How Much Is Too Much?
"I take probably 35 supplements a day. I spread them out three times a day," Kim Kardashian said during a recent appearance on Amy Poehler's podcast.
-
Training The Same Muscle Daily For 1 Week: Smart Hack Or Risky Move?
Muscle growth does not happen while you are lifting weights. It happens during recovery, through a process called muscle protein synthesis.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Chronic Use Of Melatonin Can Be Harmful, Warns Neurologist; All Side Effects Explained
Melatonin supplements work by promoting the onset of sleep, making it easier for individuals to fall asleep and improve overall sleep quality.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Covid Vaccine Claims Go Viral After Elon Musk's Comments; Experts Explain What The Evidence Shows
Covid-19 vaccine claims made by Elon Musk have recently shifted public discourse on the vaccine's efficacy. Here is what medical health authorities, doctors, and scientific data indicate about the efficacy of the COVID-19 vaccine.
-
Not Just Disrupted Sleep, New Study Says Drinking Coffee At Night Can Lead To Risky Behaviour In Women
A new study finds that drinking coffee at night may do more than disrupt sleep, it could increase impulsive and risky behaviour, especially in women.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Kim Kardashian Says She Takes 35 Supplements A Day; How Much Is Too Much?
"I take probably 35 supplements a day. I spread them out three times a day," Kim Kardashian said during a recent appearance on Amy Poehler's podcast.
-
Training The Same Muscle Daily For 1 Week: Smart Hack Or Risky Move?
Muscle growth does not happen while you are lifting weights. It happens during recovery, through a process called muscle protein synthesis.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Chronic Use Of Melatonin Can Be Harmful, Warns Neurologist; All Side Effects Explained
Melatonin supplements work by promoting the onset of sleep, making it easier for individuals to fall asleep and improve overall sleep quality.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Covid Vaccine Claims Go Viral After Elon Musk's Comments; Experts Explain What The Evidence Shows
Covid-19 vaccine claims made by Elon Musk have recently shifted public discourse on the vaccine's efficacy. Here is what medical health authorities, doctors, and scientific data indicate about the efficacy of the COVID-19 vaccine.
-
Not Just Disrupted Sleep, New Study Says Drinking Coffee At Night Can Lead To Risky Behaviour In Women
A new study finds that drinking coffee at night may do more than disrupt sleep, it could increase impulsive and risky behaviour, especially in women.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
